NCT05006521View on ClinicalTrials.gov

Single and Multiple Ascending Dose Study of KN-002

PHASE1CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

December 20, 2023

Study Completion Date

July 25, 2024

Conditions
Asthma COPD
Interventions
DRUG

KN-002

KN-002 dry powder inhaler

Trial Locations (1)

M23 9QZ

Medicines Evaluation Unit, Manchester

Sponsors
All Listed Sponsors
lead

Kinaset Therapeutics Inc

INDUSTRY